Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) that has been studied extensively in clinical and preclinical settings for its potent stimulation of growth hormone (GH) secretion via the ghrelin receptor (GHS-R1a). Research suggests it is among the strongest GHRPs available, but its tendency to elevate cortisol and prolactin at higher doses — along with rapid desensitization of the GH response — makes dosing strategy a critical variable in any research protocol.
Hexarelin GHRP research has garnered significant attention since the peptide was first synthesized in the 1990s. As a hexapeptide analog of met-enkephalin, Hexarelin (also known as Examorelin) acts on the growth hormone secretagogue receptor to trigger pulsatile GH release from the anterior pituitary. Its potency, receptor pharmacology, and dose-dependent side effect profile have made it a valuable tool for investigating the GH axis, cardiac tissue biology, and neuroendocrine regulation. This article provides a comprehensive overview of published Hexarelin research, reported dosing protocols, reconstitution guidelines, and key considerations for researchers.
What Is Hexarelin? Mechanism and Pharmacology
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide that belongs to the growth hormone-releasing peptide family. It was developed as a structural modification of GHRP-6, with the substitution of a 2-methyl-tryptophan residue that confers greater metabolic stability and enhanced GH-releasing potency.
Hexarelin exerts its primary effect by binding to the GHS-R1a receptor, the same receptor activated by the endogenous ligand ghrelin. Upon receptor activation, intracellular calcium signaling cascades in pituitary somatotrophs lead to the release of stored growth hormone. Notably, Hexarelin’s mechanism is distinct from — and synergistic with — growth hormone-releasing hormone (GHRH), which signals through a separate receptor (GHRH-R) using cyclic AMP as a second messenger.
Unlike ghrelin, Hexarelin demonstrates relatively low appetite-stimulating (orexigenic) activity in research models, although some increase in hunger has been reported. This characteristic distinguishes it from GHRP-6, which is well-known for its pronounced appetite stimulation. Hexarelin also shows binding affinity for the CD36 scavenger receptor, a finding that has spurred research into its potential effects on cardiac tissue, fatty acid uptake, and atherosclerotic plaque biology.
Key Research Findings on Hexarelin
A substantial body of peer-reviewed literature has examined Hexarelin across multiple domains. Below are some of the most significant findings:
Growth Hormone Release: In human clinical studies, Hexarelin has consistently demonstrated robust GH elevation. A landmark study by Ghigo et al. (1994) showed that intravenous administration of Hexarelin at 1–2 µg/kg produced significant GH peaks in healthy adults, with responses exceeding those of GHRP-6 at equivalent doses. Peak GH levels were typically observed 15–30 minutes post-administration.
Desensitization: One of the most important findings in Hexarelin research is the attenuation of GH response with repeated dosing. Studies have shown that continuous or frequent administration over periods as short as 4–8 weeks can lead to a significant reduction in peak GH output. Rahim et al. (1998) reported that twice-daily subcutaneous Hexarelin administration in elderly subjects produced progressively diminished GH responses over 16 weeks, though levels remained above baseline.
Cardiac Research: Hexarelin’s interaction with CD36 receptors on cardiac cells has opened a distinct line of investigation. Bhatt et al. and other research groups have demonstrated that Hexarelin may exert cardioprotective effects in animal models of ischemia-reperfusion injury, independent of GH release. These findings have prompted interest in Hexarelin as a research tool for studying myocardial protection pathways.
Cortisol and Prolactin Elevation: Unlike some milder GHRPs (such as Ipamorelin), Hexarelin has been shown to dose-dependently increase cortisol and prolactin. These effects are generally modest at lower doses but become more pronounced at dosages exceeding 1–2 µg/kg, which is a significant consideration when designing research protocols.
Hexarelin Dosing Protocols in Published Research
Dosing in Hexarelin studies has varied considerably depending on the route of administration, subject population, and research objective. The following table summarizes dosing ranges reported in published literature:
| Parameter | Details |
|---|---|
| Common Research Dose Range | 1–2 µg/kg body weight per administration |
| Typical Fixed Dose (Subcutaneous) | 100–200 µg per injection |
| Administration Frequency | 1–3 times daily in most protocols |
| Route of Administration | Subcutaneous (most common), intravenous, intranasal |
| Studied Protocol Duration | Acute (single dose) to 16 weeks |
| Optimal Timing | Fasted state; pre-sleep or post-exercise in some protocols |
| Desensitization Onset | Reported as early as 4 weeks with continuous use |
| Saturation Dose (GH Response Ceiling) | Approximately 2 µg/kg; higher doses do not proportionally increase GH |
Research suggests that the GH response to Hexarelin follows a saturation curve — doses beyond approximately 2 µg/kg do not yield proportionally greater GH output but do increase the likelihood of cortisol and prolactin elevation. For this reason, most research protocols remain within the 1–2 µg/kg window.
Some investigators have explored intermittent dosing schedules (e.g., 5 days on / 2 days off, or pulsed cycles of 4–8 weeks with rest periods) as a strategy to mitigate desensitization, although controlled data comparing continuous versus intermittent protocols remain limited.
Reconstitution and Handling Guidelines
Hexarelin is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use. Proper handling is essential for maintaining peptide integrity and ensuring accurate dosing in research applications.
| Step | Guideline |
|---|---|
| Reconstitution Solvent | Bacteriostatic water (BAC water) or sterile water for injection |
| Reconstitution Volume (Example) | 2 mL BAC water per 5 mg vial = 2,500 µg/mL concentration |
| Mixing Technique | Gently swirl or roll the vial; do not shake vigorously |
| Storage (Pre-Reconstitution) | Refrigerated (2–8°C) or frozen (−20°C) for long-term |
| Storage (Post-Reconstitution) | Refrigerated (2–8°C); use within 3–4 weeks |
| Light Sensitivity | Store away from direct light |
| Injection Volume Calculation | Desired dose (µg) ÷ concentration (µg/mL) = injection volume (mL) |
For example, if a 5 mg vial is reconstituted with 2 mL of bacteriostatic water, the resulting concentration is 2,500 µg/mL. A 200 µg dose would require drawing 0.08 mL (or 8 units on a standard U-100 insulin syringe). Researchers should always verify peptide purity through third-party certificates of analysis (COAs) before incorporating any peptide into a protocol.
Track your peptide protocol
Log every dose, cost, and observation in one organized spreadsheet.
Hexarelin Compared to Other GHRPs
Understanding how Hexarelin compares to other growth hormone-releasing peptides helps contextualize its unique profile. The GHRP family includes several well-studied compounds, each with distinct potency, selectivity, and side effect characteristics.
| Peptide | Relative GH Potency | Cortisol Impact | Prolactin Impact | Appetite Stimulation | Desensitization Risk |
|---|---|---|---|---|---|
| Hexarelin | Very High | Moderate | Moderate | Mild | High |
| GHRP-6 | High | Mild–Moderate | Mild–Moderate | Strong | Moderate |
| GHRP-2 | High | Mild–Moderate | Mild–Moderate | Moderate | Moderate |
| Ipamorelin | Moderate | Minimal | Minimal | Minimal | Low |
Hexarelin stands out for its potent GH-releasing capacity, making it particularly useful in studies designed to maximally stimulate the somatotroph axis. However, its higher desensitization risk and moderate cortisol/prolactin effects have led some researchers to favor Ipamorelin or GHRP-2 for longer-duration protocols where a cleaner side effect profile is desired.
When combined with a GHRH analog such as Modified GRF (1-29) — commonly known as CJC-1295 without DAC — the synergistic GH response is substantially amplified. Published data suggest that GHRP + GHRH combinations can produce GH peaks several-fold greater than either peptide alone, due to their complementary mechanisms of action on the pituitary.
Safety Observations and Limitations in Research
Clinical trials and preclinical studies have generally characterized Hexarelin as well-tolerated at standard research doses. The most commonly reported observations include transient flushing, mild dizziness, and localized injection site reactions. As noted, dose-dependent increases in cortisol and prolactin represent the primary neuroendocrine concerns, particularly with chronic administration.
The desensitization phenomenon remains the most significant practical limitation. Researchers working with Hexarelin should account for this variable when designing multi-week protocols and may wish to incorporate washout periods or use GH provocation testing to assess ongoing receptor sensitivity.
It is also worth noting that Hexarelin is included on the World Anti-Doping Agency (WADA) prohibited list under the category of growth hormone secretagogues, which limits its use in certain populations and contexts.
Summary and Research Considerations
Hexarelin remains one of the most extensively studied synthetic growth hormone-releasing peptides, with a well-characterized pharmacological profile that includes potent GH stimulation, GHS-R1a and CD36 receptor activity, and dose-dependent neuroendocrine effects. Its high potency makes it a valuable investigational tool, while its desensitization profile and cortisol/prolactin activity require careful protocol design.
Researchers interested in Hexarelin protocols should prioritize verified peptide sourcing, proper reconstitution and storage, and systematic tracking of dosing variables and observed outcomes. As the broader field of growth hormone secretagogue research continues to evolve, Hexarelin’s unique combination of potency and receptor pharmacology ensures it will remain a relevant subject of scientific inquiry.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.